Literature DB >> 18855724

CXCR4 receptor as a promising target for oncolytic drugs.

Yan Lavrovsky1, Yan A Ivanenkov, Konstantin V Balakin, Darya A Medvedeva, Alexandre V Ivachtchenko.   

Abstract

There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855724     DOI: 10.2174/138955708785909907

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN: 1389-5575            Impact factor:   3.862


  3 in total

1.  Elevated expression of CXC chemokines in pediatric osteosarcoma patients.

Authors:  Yiting Li; Ricardo Flores; Alexander Yu; M Fatih Okcu; Jeffrey Murray; Murali Chintagumpala; John Hicks; Ching C Lau; Tsz-Kwong Man
Journal:  Cancer       Date:  2010-08-30       Impact factor: 6.860

2.  High-level expression of CXCR4 in breast cancer is associated with early distant and bone metastases.

Authors:  Chin-Sheng Hung; Hou-Yu Su; Hung-Hwa Liang; Chieh-Wen Lai; Yo-Cheng Chang; Yuan-Soon Ho; Chih-Hsiung Wu; Jau-De Ho; Po-Li Wei; Yu-Jia Chang
Journal:  Tumour Biol       Date:  2013-10-08

3.  Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells.

Authors:  Yu-Ri Kim; Ki-Seong Eom
Journal:  Immune Netw       Date:  2014-12-22       Impact factor: 6.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.